219 related articles for article (PubMed ID: 29779223)
21. Development of a CRISPR/Cas9 System for Methylococcus capsulatus
Tapscott T; Guarnieri MT; Henard CA
Appl Environ Microbiol; 2019 Jun; 85(11):. PubMed ID: 30926729
[TBL] [Abstract][Full Text] [Related]
22. A piggyBac-based toolkit for inducible genome editing in mammalian cells.
Schertzer MD; Thulson E; Braceros KCA; Lee DM; Hinkle ER; Murphy RM; Kim SO; Vitucci ECM; Calabrese JM
RNA; 2019 Aug; 25(8):1047-1058. PubMed ID: 31101683
[TBL] [Abstract][Full Text] [Related]
23. Enhanced genome editing in mammalian cells with a modified dual-fluorescent surrogate system.
Zhou Y; Liu Y; Hussmann D; Brøgger P; Al-Saaidi RA; Tan S; Lin L; Petersen TS; Zhou GQ; Bross P; Aagaard L; Klein T; Rønn SG; Pedersen HD; Bolund L; Nielsen AL; Sørensen CB; Luo Y
Cell Mol Life Sci; 2016 Jul; 73(13):2543-63. PubMed ID: 26755436
[TBL] [Abstract][Full Text] [Related]
24. CRISPR/Cas9-mediated genome editing in sea urchins.
Lin CY; Oulhen N; Wessel G; Su YH
Methods Cell Biol; 2019; 151():305-321. PubMed ID: 30948015
[TBL] [Abstract][Full Text] [Related]
25. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.
Ohmori T; Nagao Y; Mizukami H; Sakata A; Muramatsu SI; Ozawa K; Tominaga SI; Hanazono Y; Nishimura S; Nureki O; Sakata Y
Sci Rep; 2017 Jun; 7(1):4159. PubMed ID: 28646206
[TBL] [Abstract][Full Text] [Related]
26. Efficient oligo nucleotide mediated CRISPR-Cas9 gene editing in Aspergilli.
Nødvig CS; Hoof JB; Kogle ME; Jarczynska ZD; Lehmbeck J; Klitgaard DK; Mortensen UH
Fungal Genet Biol; 2018 Jun; 115():78-89. PubMed ID: 29325827
[TBL] [Abstract][Full Text] [Related]
27. AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells In Vivo.
Hung SS; Chrysostomou V; Li F; Lim JK; Wang JH; Powell JE; Tu L; Daniszewski M; Lo C; Wong RC; Crowston JG; Pébay A; King AE; Bui BV; Liu GS; Hewitt AW
Invest Ophthalmol Vis Sci; 2016 Jun; 57(7):3470-6. PubMed ID: 27367513
[TBL] [Abstract][Full Text] [Related]
28. In Vivo AAV-CRISPR/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia.
Zhao H; Li Y; He L; Pu W; Yu W; Li Y; Wu YT; Xu C; Wei Y; Ding Q; Song BL; Huang H; Zhou B
Circulation; 2020 Jan; 141(1):67-79. PubMed ID: 31779484
[TBL] [Abstract][Full Text] [Related]
29. The Synergy between CRISPR and Chemical Engineering.
Lau CH; Tin C
Curr Gene Ther; 2019; 19(3):147-171. PubMed ID: 31267870
[TBL] [Abstract][Full Text] [Related]
30. Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice.
Li L; Song L; Liu X; Yang X; Li X; He T; Wang N; Yang S; Yu C; Yin T; Wen Y; He Z; Wei X; Su W; Wu Q; Yao S; Gong C; Wei Y
ACS Nano; 2017 Jan; 11(1):95-111. PubMed ID: 28114767
[TBL] [Abstract][Full Text] [Related]
31. CRISPR/Cas9-mediated genome editing of splicing mutation causing congenital hearing loss.
Ryu N; Kim MA; Choi DG; Kim YR; Sonn JK; Lee KY; Kim UK
Gene; 2019 Jun; 703():83-90. PubMed ID: 30898719
[TBL] [Abstract][Full Text] [Related]
32. A multifunctional AAV-CRISPR-Cas9 and its host response.
Chew WL; Tabebordbar M; Cheng JK; Mali P; Wu EY; Ng AH; Zhu K; Wagers AJ; Church GM
Nat Methods; 2016 Oct; 13(10):868-74. PubMed ID: 27595405
[TBL] [Abstract][Full Text] [Related]
33. CASAAV: A CRISPR-Based Platform for Rapid Dissection of Gene Function In Vivo.
VanDusen NJ; Guo Y; Gu W; Pu WT
Curr Protoc Mol Biol; 2017 Oct; 120():31.11.1-31.11.14. PubMed ID: 28967995
[TBL] [Abstract][Full Text] [Related]
34. Highly efficient neuronal gene knockout in vivo by CRISPR-Cas9 via neonatal intracerebroventricular injection of AAV in mice.
Hana S; Peterson M; McLaughlin H; Marshall E; Fabian AJ; McKissick O; Koszka K; Marsh G; Craft M; Xu S; Sorets A; Torregrosa T; Sun C; Henderson CE; Lo SC
Gene Ther; 2021 Nov; 28(10-11):646-658. PubMed ID: 33558692
[TBL] [Abstract][Full Text] [Related]
35. CRISPR/Cas9: targeted genome editing for the treatment of hereditary hearing loss.
Farooq R; Hussain K; Tariq M; Farooq A; Mustafa M
J Appl Genet; 2020 Feb; 61(1):51-65. PubMed ID: 31912450
[TBL] [Abstract][Full Text] [Related]
36. CRISPR/Cas9 targeting events cause complex deletions and insertions at 17 sites in the mouse genome.
Shin HY; Wang C; Lee HK; Yoo KH; Zeng X; Kuhns T; Yang CM; Mohr T; Liu C; Hennighausen L
Nat Commun; 2017 May; 8():15464. PubMed ID: 28561021
[TBL] [Abstract][Full Text] [Related]
37. Highly efficient 'hit-and-run' genome editing with unconcentrated lentivectors carrying Vpr.Prot.Cas9 protein produced from RRE-containing transcripts.
Indikova I; Indik S
Nucleic Acids Res; 2020 Aug; 48(14):8178-8187. PubMed ID: 32619241
[TBL] [Abstract][Full Text] [Related]
38. The Development of an AAV-Based CRISPR SaCas9 Genome Editing System That Can Be Delivered to Neurons
Kumar N; Stanford W; de Solis C; Aradhana ; Abraham ND; Dao TJ; Thaseen S; Sairavi A; Gonzalez CU; Ploski JE
Front Mol Neurosci; 2018; 11():413. PubMed ID: 30483052
[TBL] [Abstract][Full Text] [Related]
39. In Vivo Investigation of Gene Function in Muscle Stem Cells by CRISPR/Cas9-Mediated Genome Editing.
He L; He Z; Li Y; Sun H; Wang H
Methods Mol Biol; 2023; 2640():287-311. PubMed ID: 36995603
[TBL] [Abstract][Full Text] [Related]
40. Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice.
Ling S; Yang S; Hu X; Yin D; Dai Y; Qian X; Wang D; Pan X; Hong J; Sun X; Yang H; Paludan SR; Cai Y
Nat Biomed Eng; 2021 Feb; 5(2):144-156. PubMed ID: 33398131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
